Abstract | BACKGROUND AND PURPOSE: METHODS: A systematic Medline/PubMed literature search of peer-reviewed scientific articles in urology and cardiovascular medicine was performed concerning the management of anticoagulative and antiplatelet medication during SWL. RESULTS: The literature on medically acquired and pathological bleeding diathesis and SWL in general is rare, retrospective, nonstandardized, and of low quality. Routine cessation of obligatory indicated anticoagulative or antiplatelet medication implies a significant risk for cardiovascular adverse events (CAE). Ureterorenoscopy is recommended in patients with uncorrected bleeding diathesis, although this is not based on high-level evidence. CONCLUSION: In patients with obligatory intake of anticoagulative or antiplatelet medication, the risk for CAE must be balanced against the SWL-induced bleeding risk. In patients with low-dose ASA-intake, SWL should be considered as an option instead of being disregarded as an absolute contraindication. Prospective randomized trials designed to define the optimal management of anticoagulants and antiplatelets during SWL are warranted.
|
Authors | Marco J Schnabel, Michael Gierth, Johannes Bründl, Christian G Chaussy, Maximilian Burger, Hans-Martin Fritsche |
Journal | Journal of endourology
(J Endourol)
Vol. 28
Issue 9
Pg. 1034-9
(Sep 2014)
ISSN: 1557-900X [Electronic] United States |
PMID | 24851726
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticoagulants
- Platelet Aggregation Inhibitors
- Aspirin
|
Topics |
- Anticoagulants
(administration & dosage)
- Aspirin
(administration & dosage)
- Cardiovascular Diseases
(prevention & control)
- Contraindications
- Disease Susceptibility
- Hemorrhage
(etiology, prevention & control)
- Humans
- Kidney Calculi
(therapy)
- Lithotripsy
(adverse effects)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Prospective Studies
- Retrospective Studies
- Ureteral Calculi
(therapy)
- Ureteroscopy
|